$VRSK

Hansen Bruce Edward sold $400K of VRSK

Hansen Bruce Edward sold 2,335 shares of Verisk Analytics, Inc. (VRSK) at $171.51 ($0.40M total) on 2026-05-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hansen Bruce Edward
Published May 26, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

Insider sales can influence short-term sentiment, but 10b5-1 plans are designed to mitigate timing-based trading signals, lowering fundamental interpretation.

02

Market read

A routine director 10b5-1 sale is unlikely to change valuation drivers absent additional company news.

03

What to watch

Check for clustering of insider trades around the same period and whether other filings (earnings, guidance, contracts) occurred concurrently; none are mentioned here.

Relevance 6/10Timing: Disclosure filed 2026-05-26 for a sale dated 2026-05-22; any reaction is typically short-lived.

Background

The article is an SEC Form 4 insider transaction: a director reports an open-market sale of Verisk Analytics shares, with a Rule 10b5-1 pre-arranged plan.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk Analytics director Hansen Bruce Edward sold 2,335 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven and should fade unless corroborated by other news.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and no accompanying operational or financial catalyst.

Market effects

Minimal; this is company-specific insider activity without sector-wide guidance or regulatory signals.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Verisk Analytics, Inc.

    Subject of the Form 4 insider sale disclosure by a director.

  • Hansen Bruce Edward

    Director who sold 2,335 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer